ANDA 77209, held by TP ANDA Holdings. Cyclobenzaprine Hydrochloride.
As of Nov 21, 2026, ANDA 77209 (Cyclobenzaprine Hydrochloride), held by TP ANDA Holdings, was first approved by FDA on Oct 4, 2005, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 4, 2005 | Original application | Approved |
| Cyclobenzaprine Hydrochloride10MG · tablet;oral | Cyclobenzaprine Hydrochloride | Rx |
| Cyclobenzaprine Hydrochloride5MG · tablet;oral | Cyclobenzaprine Hydrochloride | Rx |
| Jul 31, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 4, 2005 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters